IRulya Therapeutics, Inc. (IRLA)
32.95
+1.33
(+4.21%)
USD |
NASDAQ |
Oct 30, 16:00
33.50
+0.55
(+1.67%)
After-Hours: 20:00
IRulya Therapeutics Net Income (Quarterly) : -75.49M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -75.49M |
| March 31, 2026 | 35.91M |
| December 31, 2025 | -39.46M |
| September 30, 2025 | -13.44M |
| June 30, 2025 | -16.05M |
| March 31, 2025 | -15.03M |
| December 31, 2024 | -12.46M |
| September 30, 2024 | -5.492M |
| June 30, 2024 | -27.73M |
| March 31, 2024 | -11.15M |
| December 31, 2023 | -8.894M |
| September 30, 2023 | -5.351M |
| June 30, 2023 | -4.886M |
| March 31, 2023 | -12.25M |
| December 31, 2022 | -5.534M |
| September 30, 2022 | -7.921M |
| Date | Value |
|---|---|
| June 30, 2022 | -16.56M |
| March 31, 2022 | -21.64M |
| December 31, 2021 | -23.40M |
| September 30, 2021 | -21.71M |
| June 30, 2021 | -21.75M |
| March 31, 2021 | -23.09M |
| December 31, 2020 | -20.56M |
| September 30, 2020 | -21.51M |
| June 30, 2020 | -17.61M |
| March 31, 2020 | -17.18M |
| December 31, 2019 | -12.38M |
| September 30, 2019 | -9.858M |
| June 30, 2019 | -9.062M |
| March 31, 2019 | -5.681M |
| June 30, 2018 | -3.108M |
| March 31, 2018 | -3.377M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | -1.755M |
| PepGen Inc. | -17.81M |
| Q32 Bio, Inc. | -8.946M |
| Bridgebio Oncology Therapeutics, Inc. | -56.45M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 75.49M |
| EPS Diluted (Quarterly) | -12.31 |
| Enterprise Value | 61.34M |
| Earnings Yield | -381.2% |
| Normalized Earnings Yield | -367.58 |